| Company/Division name | Evolve Biologics |
| Parent company | Evolve |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 300 |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | Canada |
| City reshored to: | Sachse |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | plasma |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Skilled workforce availability/training |
